Quantcast

Latest Vancomycin Stories

2010-09-09 07:00:00

CHAPEL HILL, N.C., Sept. 9 /PRNewswire/ -- Cempra Pharmaceuticals today announced abstracts to be presented on its oral anti-MRSA antibiotic, TAKSTA (sodium fusidate, formerly CEM-102), at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 12 to 15, 2010, in Boston. Data to be presented demonstrate that TAKSTA showed clinical success rates and tolerability comparable to oral linezolid. Presentations will also provide additional data that...

2010-09-07 12:00:00

EXTON, Pa., Sept. 7 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Stifel Nicolaus 2010 Healthcare Conference at 9:10 A.M. ET on Wednesday, September 15, 2010. The conference is being held at the Four Seasons in Boston. Vincent Milano, president and chief executive officer, of ViroPharma, will present at the Fifth Annual JMP Securities Healthcare Conference...

2010-09-02 07:00:00

SAN DIEGO, Sept. 2 /PRNewswire/ -- Results from studies related to Optimer Pharmaceuticals, Inc.'s (Nasdaq: OPTR) lead developmental product candidate, fidaxomicin, will be presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held at the Boston Convention and Exhibition Center in Boston on September 12-15, 2010. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) (Logo:...

2010-08-19 07:00:00

SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the European Medicines Agency (EMA) has accepted for review Optimer's Marketing Authorization Application (MAA) for fidaxomicin for the treatment of patients with Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI in the European Union (EU). Optimer announced the submission of its MAA for fidaxomicin to the EMA on August 2, 2010. (Logo:...

2010-07-29 07:00:00

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it has submitted a Marketing Authorization Application (MAA) for fidaxomicin to the European Medicines Agency (EMA) under the European Union's Centralized Procedure. Optimer is seeking approval to market fidaxomicin for the treatment of patients with Clostridium difficile infection (CDI). (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) (Logo:...

2010-07-26 07:00:00

CHICAGO, July 26 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has entered into a sponsored research and option agreement with The University of British Columbia (UBC) to develop several antimicrobial peptides. These peptides exhibit...

2010-07-21 11:00:00

EXTON, Pa., July 21 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) second quarter financial results for 2010 are expected to be released on Wednesday, July 28, 2010 before the open of the U.S. financial markets. The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2010 second quarter financial results and other business. The press release and the...

2010-07-08 07:00:00

SAN DIEGO, July 8 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced it has received a $500,000 milestone payment from Cempra Pharmaceuticals, Inc. pursuant to the terms of a licensing agreement between the companies. The milestone payment was made as a result of Cempra's continuing development of a next-generation macrolide (CEM-101) for the treatment of respiratory infections. Cempra licensed CEM-101 from Optimer and has successfully completed a Phase...

f6179f030f4a0e8406f0c3e2b2e241ef1
2010-06-28 09:44:54

Bees could have a key role to play in urgently-needed new treatments to fight the virulent MRSA bug, according to research led at the University of Strathclyde. The scientists found that a substance known as beeglue or propolis, originating from beehives in the Pacific region, was active against MRSA, which causes potentially fatal infections, particularly in hospital patients. The bug was either the underlying cause or a contributory factor in more than 1,900 deaths between 1996 and 2008....

2010-06-22 07:00:00

MALVERN, Pa., June 22 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that surveyed infectious disease specialists anticipate changes in their future prescribing patterns for treating hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections. Physicians want to continue gaining experience with currently branded anti-infectives such as Cubist's Cubicin,...


Latest Vancomycin Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »
Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related